Table of Contents

High blood sugar can damage the kidneys’ filtering units, making diabetes a leading cause of chronic kidney disease (CKD) and end-stage kidney disease. About 40% of people with type 2 diabetes develop CKD, and the risk increases the longer the disease lasts. Between 2017 and 2020, 39.2% of end-stage kidney disease cases in US adults with diabetes were linked directly to diabetes, more than any other cause.

Given this strong link between diabetes and kidney failure, researchers have focused on finding medications that can slow the damage. One such option is Ozempic (semaglutide), a GLP-1 receptor agonist.

This article explores how Ozempic may help protect kidney function, along with the benefits, risks, and key considerations for people with or at risk for CKD.

Key Takeaways

  • Ozempic is now an FDA-approved option for slowing kidney decline in patients with type 2 diabetes and CKD.
  • The kidney benefits of Ozempic aren’t solely due to improved glucose levels. Its influence on weight reduction, blood pressure, and markers of inflammation and oxidative stress may also contribute.
  • Reductions in albumin levels in urine seen across SUSTAIN trials suggest that Ozempic helps restore the integrity of the kidney’s filtering mechanism, especially in patients with early signs of kidney injury.
  • The FLOW trial and post hoc analyses from earlier SUSTAIN trials consistently showed slower kidney function decline, fewer adverse kidney outcomes, and reduced cardiovascular risks among Ozempic users.

The Kidney-Diabetes Connection

Doctor with patient with model of kidney on desk

Inside the kidneys are tiny filtering units called nephrons. Each nephron contains a cluster of small blood vessels called glomeruli. Persistently high glucose (sugar) levels damage these glomeruli, making them leaky or scarred. This leads to protein leaking into the urine (proteinuria), one of the first signs of kidney damage.

As more nephrons are damaged, the kidneys lose their ability to remove toxins, balance fluids, and regulate electrolytes. This can eventually lead to chronic kidney disease (CKD) and, in severe cases, end-stage kidney disease (ESKD), where dialysis or a transplant is needed.

Additionally, diabetes often coexists with high blood pressure, which puts additional stress on the kidney vessels. Other factors strongly linked to CKD in people with type 2 diabetes include:

    • Older age
    • Obesity
    • History and duration of diabetes
    • Smoking
    • Heart disease

Studies show that people with diabetes have 1.3 to 4.6 times higher odds of having CKD compared to those without diabetes. This risk becomes even greater if they also have high blood pressure. In the US, about 26.2% of adults with diabetes had CKD (based on persistent protein in the urine or low kidney filtration rate).

Can You Use Ozempic for Kidney Disease?

Yes, the FDA approved Ozempic (semaglutide) for reducing the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD. It’s the first GLP-1 receptor agonist approved for this use.

Early signs of kidney benefits came from the SUSTAIN 6 trial. A post hoc analysis looked at how Ozempic affected kidney health based on patients’ initial kidney risk levels. Those who took Ozempic were 69% more likely to move into a lower risk category and 29% less likely to move into a worse one.

The FLOW trial provided more solid evidence. This large study followed over 3,500 people with type 2 diabetes and CKD for more than three years. It found a 24% drop in the combined risk of kidney failure, major kidney function decline, or death from kidney or heart-related causes in those taking Ozempic.

Secondary outcomes include:

Outcome Result with Ozempic vs. Placebo
Rate of eGFR decline (a measure of how well your kidneys are filtering waste from your blood) Slowed by 1.16 mL/min/1.73m²/year
Major cardiovascular events Reduced by 18%
All-cause mortality Reduced by 20%
These results led to FDA approval of Ozempic in 2025 for slowing CKD progression in patients with type 2 diabetes.

How Ozempic Helps Protect Kidney Function

While better blood sugar control likely contributes to Ozempic’s kidney benefits, other mechanisms may also be involved, such as:

1. Lowers Blood Pressure

High blood pressure can make blood vessels tighten and become narrow, including the ones in your kidneys. When the kidneys don’t get enough blood, they can’t filter waste and extra fluid properly. The fluid then builds up in your body and raises your blood pressure even more. This creates a harmful cycle that can eventually lead to kidney failure.

Ozempic has been shown to lower blood pressure. In one study, researchers reviewed 29 high-quality clinical trials that included nearly 27,000 people with type 2 diabetes. Results showed that semaglutide dropped systolic blood pressure (SBP) by about 2.3 mmHg on average.

Another study looked at 22 clinical trials involving a total of 15,347 people. Results showed that systolic BP dropped by 2.90 mmHg and diastolic BP dropped by 0.86 mmHg in people using semaglutide.

2. Promotes Weight Loss

Many large studies have shown that being overweight or obese increases the risk of developing and worsening kidney disease. The risk is especially higher in people with class II obesity or worse (BMI greater than or equal to 35), and the disease tends to progress faster in those who already have CKD.

It’s well-established that Ozempic causes significant weight loss as it reduces appetite, slows down stomach emptying, and makes you feel full longer. This naturally leads to eating less and, over time, losing weight.

In clinical trials (like SUSTAIN and STEP studies), people taking Ozempic lost 10 to 15 pounds on average (at 1 mg/week). Some lost even more at higher doses.

Interested in How Ozempic Affects Weight?

Explore more in-depth guides:

3. Reduces Inflammation and Oxidative Stress

When the kidneys are injured, due to diabetes, high blood pressure, or toxins, the body triggers an inflammatory response. This response is meant to support healing. But if the inflammation becomes long-term (chronic), it starts causing harm instead. It can damage the small blood vessels and filtering units in the kidneys. Eventually, this leads to scarring (called fibrosis), which limits how well the kidneys work.

Oxidative stress is another factor that worsens kidney damage. It occurs when there’s an imbalance between free radicals (harmful molecules) and antioxidants (which protect your cells). Excess free radicals damage kidney cells, proteins, and DNA.

Stages of Oxidative Stress

Inflammation and oxidative stress often make each other worse. Inflammation can increase the production of free radicals, and those free radicals can trigger even more inflammation.

Ozempic has been shown to reduce inflammation throughout the body. In small clinical studies, people who took 1 mg of Ozempic weekly for six months had lower levels of inflammatory markers like IL-6 and TNF-? in their blood. Another study found that it also lowered high-sensitivity C-reactive protein (hsCRP), another indicator of inflammation.

Semaglutide may also help by lowering oxidative stress. In lab studies, it reduced levels of reactive oxygen species (ROS), harmful molecules that contribute to inflammation. It also helped reduce obesity-related inflammation by calming overactive immune cells in fat tissue.

4. Reduces Albuminuria

Albuminuria means that albumin, a type of protein normally kept in the blood, is being leaked into the urine. Healthy kidneys usually prevent albumin from passing through their filters. When the kidneys are damaged, their filtering ability becomes impaired, allowing albumin to pass into the urine.

In clinical practice:

    • Microalbuminuria (30-300 mg/day) signals early kidney damage.
    • Macroalbuminuria (>300 mg/day) suggests more advanced damage.

Researchers conducted a post-hoc analysis using data from several past SUSTAIN trials (1 to 7), which included over 8,400 participants. Ozempic significantly reduced the amount of albumin in urine, especially in people who already had early kidney issues like microalbuminuria.

In one large analysis (SUSTAIN 1-5), albuminuria dropped by ~16% with Ozempic 1.0 mg. Meanwhile, it increased by ~24% with the placebo. Across all studies, Ozempic users did not experience more kidney-related side effects than those on placebo or other diabetes drugs.

Important!

There have been some rare reports of acute kidney injury (AKI) in people taking Ozempic. Some of these cases were severe enough to require dialysis. However, these problems mostly happened in people who had severe nausea, vomiting, or diarrhea, which can lead to dehydration, a known trigger for kidney problems.

Wrap-up

Using Ozempic for kidney disease requires close monitoring. The drug may offer kidney protection through better glucose control, weight reduction, and reduced inflammation. However, gastrointestinal side effects that lead to fluid loss can be risky if not managed carefully.

If you’re considering Ozempic, especially with existing renal issues, partner closely with your doctor to weigh the benefits and potential risks.

Frequently Asked Questions

Ozempic shows notable kidney-protective effects in people with type 2 diabetes and chronic kidney disease, including reducing major kidney events by roughly 24% in the FLOW trial. However, rare post-marketing reports have noted instances of acute kidney injury or worsening CKD linked to semaglutide. It’s deemed safe under medical supervision but requires monitoring in at-risk patients.

Originally approved for type 2 diabetes and later for reducing cardiovascular risk, Ozempic received FDA approval on January 28, 2025, to also slow CKD progression, prevent kidney failure, and reduce cardiovascular mortality in adults with type 2 diabetes and chronic kidney disease.

There are no separate renal dosing guidelines. Ozempic dosing (starting at 0.25?mg weekly and titrating up) remains the same regardless of kidney function, as it’s primarily metabolized rather than renally excreted.

Yes. Under Medicare Part?D, Ozempic is covered if prescribed for FDA-approved uses, type 2 diabetes, cardiovascular risk reduction, or slowing kidney disease progression in type 2 diabetics, but not for weight loss or prediabetes. Prior authorization may be required, and coverage can vary across plans and states.

Wegovy contains semaglutide and has been linked to a roughly 22% lower rate of kidney-related complications in overweight or obese individuals, and it is considered safe in those with kidney impairment.

While Ozempic hasn’t been shown to directly decrease serum creatinine, it slows eGFR decline and improves kidney outcomes like albuminuria, lowering the risk of progression to kidney failure by about 16-24%. These benefits may indirectly support better creatinine trends over time.

Related Articles

Sources

Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018). The Global Epidemiology of Diabetes and Kidney Disease. Advances in chronic kidney disease, 25(2), 121–132. https://doi.org/10.1053/j.ackd.2017.10.011

Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine, 391(2), 109–121. https://doi.org/10.1056/nejmoa2403347

Tuttle, K. R., Bain, S. C., Bosch-Traberg, H., Khunti, K., Rasmussen, S., Sokareva, E., & Cherney, D. Z. (2024). Effects of Once-Weekly semaglutide on kidney Disease outcomes by KDIGO Risk category in the SUSTAIN 6 trial. Kidney International Reports, 9(7), 2006–2015. https://doi.org/10.1016/j.ekir.2024.04.028

News details. (2025, January 29). Novo Nordisk. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915253

High Blood Pressure & Kidney Disease. (2025, April 22). National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/kidney-disease/high-blood-pressure

Wu, W., Tong, H., Li, Y., & Cui, J. (2023). The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis. Endocrine, 83(3), 571–584. https://doi.org/10.1007/s12020-023-03636-9

Li, Y., Xue, K., Hu, R., Hu, X., Guo, R., Guo, H., & Li, G. (2025). Meta-analysis of the effect of semaglutide on blood pressure in obese populations. SpringerLink. https://doi.org/10.1007/s40256-025-00738-9

Kovesdy, C. P., Furth, S. L., Zoccali, C., & World Kidney Day Steering Committee (2017). Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Canadian journal of kidney health and disease, 4, 2054358117698669. https://doi.org/10.1177/2054358117698669

Yaribeygi, H., Maleki, M., Jamialahmadi, T., & Sahebkar, A. (2024). Anti-inflammatory benefits of semaglutide: State of the art. Journal of clinical & translational endocrinology, 36, 100340. https://doi.org/10.1016/j.jcte.2024.100340

Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022). Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovascular Diabetology, 21(1). https://doi.org/10.1186/s12933-022-01585-7

Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020). Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. The Lancet Diabetes & Endocrinology, 8(11), 880–893. https://doi.org/10.1016/s2213-8587(20)30313-2

National Diabetes Statistics Report. (2024, May 15). Diabetes. https://www.cdc.gov/diabetes/php/data-research/index.html

Fenta, E. T., Eshetu, H. B., Kebede, N., Bogale, E. K., Zewdie, A., Kassie, T. D., Anagaw, T. F., Mazengia, E. M., & Gelaw, S. S. (2023). Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetology & Metabolic Syndrome, 15(1). https://doi.org/10.1186/s13098-023-01202-x